APLM vs. PMN, MRKR, CASI, BCTX, JAN, DRRX, FBIO, IPA, SPRB, and VIRX
Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include ProMIS Neurosciences (PMN), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), JanOne (JAN), DURECT (DRRX), Fortress Biotech (FBIO), ImmunoPrecise Antibodies (IPA), Spruce Biosciences (SPRB), and Viracta Therapeutics (VIRX). These companies are all part of the "pharmaceutical preparations" industry.
ProMIS Neurosciences (NASDAQ:PMN) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
ProMIS Neurosciences' return on equity of 0.00% beat Apollomics' return on equity.
ProMIS Neurosciences has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Apollomics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500.
In the previous week, ProMIS Neurosciences had 4 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for ProMIS Neurosciences and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.61 beat ProMIS Neurosciences' score of 0.00 indicating that ProMIS Neurosciences is being referred to more favorably in the media.
ProMIS Neurosciences has higher earnings, but lower revenue than Apollomics.
Apollomics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 80.00% of users gave Apollomics an outperform vote.
50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 10.3% of ProMIS Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ProMIS Neurosciences presently has a consensus price target of $8.00, suggesting a potential upside of 333.60%. Apollomics has a consensus price target of $2.00, suggesting a potential upside of 502.05%. Given ProMIS Neurosciences' higher possible upside, analysts clearly believe Apollomics is more favorable than ProMIS Neurosciences.
Summary
ProMIS Neurosciences beats Apollomics on 8 of the 14 factors compared between the two stocks.
Get Apollomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apollomics Competitors List
Related Companies and Tools
